The short version of GHRH analog fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-01 and is reviewed periodically as new material appears.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Since these elements comprise a large percentage of fission products, Segrè and McMillan decided that the half-life must have been simply another fission product, titling the paper "An Unsuccessful Search for Transuranium Elements". However, as more information about fission became available, the possibility that the fragments of nuclear fission could still have been present in the target became more remote. McMillan and several scientists, including Philip H. Abelson, attempted again to determine what was producing the unknown half-life. In early 1940, McMillan realized that his 1939 experiment with Segrè had failed to test the chemical reactions of the radioactive source with sufficient rigor. In a new experiment, McMillan tried subjecting the unknown substance to HF in the presence of a reducing agent, something he had not done before. This reaction resulted in the sample precipitating with the HF, an action that definitively ruled out the possibility that the unknown substance was a rare-earth metal. Shortly after this, Abelson, who had received his graduate degree from the university, visited Berkeley for a short vacation and McMillan asked the more able chemist to assist with the separation of the experiment's results. Abelson very quickly observed that whatever was producing the 2.3-day half-life did not have chemistry like any known element and was actually more similar to uranium than a rare-earth metal. This discovery finally allowed the source to be isolated and later, in 1945, led to the classification of the actinide series.
It has hitherto been necessary to postulate some special arbitrary "instability" of the nucleus, but in the following note, it is pointed out that disintegration is a natural consequence of the laws of quantum mechanics without any special hypothesis... Much has been written of the explosive violence with which the α-particle is hurled from its place in the nucleus. But from the process pictured above, one would rather say that the α-particle almost slips away unnoticed. The theory supposes that the alpha particle can be considered an independent particle within a nucleus, that is in constant motion but held within the nucleus by strong interaction. At each collision with the repulsive potential barrier of the electromagnetic force, there is a small non-zero probability that it will tunnel its way out. An alpha particle with a speed of 1.5×107 m/s within a nuclear diameter of approximately 10−14 m will collide with the barrier more than 1021 times per second. However, if the probability of escape at each collision is very small, the half-life of the radioisotope will be very long, since it is the time required for the total probability of escape to reach 50%. As an extreme example, the half-life of the isotope bismuth-209 is 2.01×1019 years. The isotopes in beta-decay stable isobars that are also stable with regards to double beta decay with mass number A = 5, A = 8, 143 ≤ A ≤ 155, 160 ≤ A ≤ 162, and A ≥ 165 are theorized to undergo alpha decay. All other mass numbers (isobars) have exactly one theoretically stable nuclide.
== Treatment == For people with the FOLR1 mutation, even when the systemic deficiency is corrected by folate (the oxidized form - folic acid), the cerebral deficiency remains, and must be treated with folinic acid. Folinic acid is a metabolically active form of folate that can be easily introduced into the folate cycle. A typical dose that is administered to children is 0.5–1 mg/kg daily, but the dose can be increased depending on the severity of symptoms and the age of the child. Over time, the treatment with folinic acid has shown to reduce a variety of symptoms of CFD. The treatment of folinic acid can lead to improvements in walking, speech, interpersonal skills and reduction in seizures. Success depends on early initiation of treatment. Starting the folinic acid treatment before the age of six is more advantageous for the child with CFD. If the treatment is started after the age of six, its results are not as effective. Treatment requires taking folinic acid for lengthy periods. Fewer than 20 people with the FOLR1 defect have been described in the medical literature. Folinic acid (5-formyl-THF, 5-fTHF) also appears useful for some other forms of CFD. Pharmacologic doses of folinic acid has also led to reversal of some symptoms in children diagnosed with cerebral folate deficiency and testing positive for autoantibodies to folate receptor alpha. It also appears useful in DHFR deficiency and AADC deficiency. 5-MTHF (5-methyl-THF) is also available as a drug (levomefolic acid). It is "thought to be the most efficient way to restore CSF 5-MTHF concentrations".
Sources: en.wikipedia.org
== 90Sr contamination in the environment == 90Sr is not quite as likely as 137Cs to be released as a part of a nuclear reactor accident because it is much less volatile, but is probably the most dangerous component of the radioactive fallout from a nuclear weapon. A study of hundreds of thousands of deciduous teeth, collected by Dr.Louise Reiss and her colleagues as part of the Baby Tooth Survey, found a large increase in 90Sr levels through the 1950s and early 1960s. The study's final results showed that children born in St. Louis, Missouri, in 1963 had levels of 90Sr in their deciduous teeth that was 50 times higher than that found in children born in 1950, before the advent of large-scale atomic testing. Reviewers of the study predicted that the fallout would cause increased incidence of disease in those who absorbed 90Sr into their bones. However, no follow up studies of the subjects have been performed, so the claim is untested. An article with the study's initial findings was circulated to U.S. President John F. Kennedy in 1961, and helped convince him to sign the Partial Nuclear Test Ban Treaty with the United Kingdom and Soviet Union, ending the above-ground nuclear weapons testing that placed the greatest amounts of nuclear fallout into the atmosphere. The Chernobyl disaster released roughly 10 PBq, or about 5% of the core inventory, of 90Sr into the environment. The Kyshtym disaster released 90Sr and other radioactive material into the environment. It is estimated to have released 20 MCi (800 PBq) of radioactivity.
=== CRISPR/Cas9 === The clustered frequently interspaced short palindromic repetitions (CRISPR)/CRISPR associated (Cas) system is a powerful method of genome engineering in a range of organisms because of its simplicity, modularity, and scalability. In this technique, a guide RNA (gRNA) attracts the CRISPR nuclease Cas9 to a particular spot in the genome, causing a double strand break. Several DNA repair processes, including homology-directed recombination and non-homology end joining, can be used to accomplish the desired genome change (i.e., gene deletion or insertion). Additionally, dCas9 (dead Cas9 or nuclease-deficient Cas9), a Cas9 double mutant (H840A, D10A), has been utilised to control gene expression in bacteria or when linked to a stimulation of suppression site in yeast.
=== Insulin-induced hypokalemia === Insulin can also cause postprandial somnolence via another mechanism. Insulin increases the activity of Na/K ATPase, causing increased movement of potassium into cells from the extracellular fluid. The large movement of potassium from the extracellular fluid can lead to a mild hypokalemic state. The effects of hypokalemia can include fatigue, muscle weakness, or paralysis. The severity of the hypokalemic state can be evaluated using Fuller's Criteria. Stage 1 is characterized by no symptoms but mild hypokalemia. Stage 2 is characterized with symptoms and mild hypokalemia. Stage 3 is characterized by only moderate to severe hypokalemia.
Sources: en.wikipedia.org
The Scoville scale is a measure of the hotness of a chili pepper. It is the degree of dilution in sugar water of a specific chili pepper extract when a panel of 5 tasters can no longer detect its "heat". Pure capsaicin (the chemical responsible for the "heat") has 16 million Scoville heat units.
AN has the highest mortality rate of any psychological disorder. The mortality rate is 11 to 12 times greater than in the general population, and the suicide risk is 56 times higher. Half of women with AN achieve a full recovery, while an additional 20–30% may partially recover. Not all people with anorexia recover completely: about 20% develop anorexia nervosa as a chronic disorder. If anorexia nervosa is not treated, serious complications such as heart conditions and kidney failure can arise and eventually lead to death. The average number of years from onset to remission of AN is seven for women and three for men. After ten to fifteen years, 70% of people no longer meet the diagnostic criteria, but many still continue to have eating-related problems. People who have autism recover more slowly, probably due to autism's effects on thinking patterns, such as reduced cognitive flexibility. Alexithymia (inability to identify and describe one's own emotions) influences treatment outcome. Recovery is also viewed on a spectrum rather than black and white. According to the Morgan-Russell criteria, individuals can have a good, intermediate, or poor outcome. Even when a person is classified as having a "good" outcome, weight only has to be within 15% of average, and normal menstruation must be present in females. The good outcome also excludes psychological health. Recovery for people with anorexia nervosa is undeniably positive, but recovery does not mean a return to normal.
The new 12th district is in the western part of the Dallas–Fort Worth metroplex, and takes in most of Parker County and western Tarrant County, including most of the western half of Fort Worth and such inner suburbs as Benbrook, Saginaw, and Haltom City, as well as Weatherford in Parker County. The incumbent is Republican Craig Goldman, who was elected with 63.5% of the vote in 2024. Donald Trump won 61.3% and Ted Cruz 57.9% in 2024.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.